Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 21, 2010Journal of Cardiovascular Pharmacology

Antithrombotic and Anticoagulant Profiles of TAK-442, a Novel Factor Xa Inhibitor, in a Rabbit Model of Venous Thrombosis

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does TAK-442 reduce thrombus formation without prolonging bleeding time in a rabbit model of venous thrombosis?

Population

Human plasma and a rabbit model of venous thrombosis

Comparison

TAK-442 administered as intravenous bolus… vs Vehicle control, melagatran, rivaroxaban, and…

Design

Preclinical

Follow-up

1-hour infusion

Authors

MKMasaki KawamuraShinshu UniversityNKNoriko KonishiJapan Tobacco (United States)KHKatsuhiko HiroePharmacology Research Institute

Discussion

Loading...

Member takes

Implication

Hypothesis-generating for TAK-442 in venous thrombosis; leaves open translation of antithrombotic efficacy without bleeding risk to humans.

Structured PICO

Does TAK-442 reduce thrombus formation without prolonging bleeding time in a rabbit model of venous thrombosis?

P
Population
Human plasma and a rabbit model of venous thrombosis
I
Intervention
TAK-442 (direct factor Xa inhibitor) administered as intravenous bolus followed by 1-hour infusion (50, 100, and 500 micrograms/kg)
C
Comparator
Vehicle control, melagatran (thrombin inhibitor), rivaroxaban, and apixaban
O
Outcome
Thrombus formation and bleeding timesurrogate

TAK-442 demonstrates potent antithrombotic effects comparable to melagatran in a rabbit model of venous thrombosis, but without the associated bleeding time prolongation.

Cite This Study

Kawamura et al. (2010) studied this question.

synapsesocial.com/papers/6a70127aac440176ef28b82fhttps://doi.org/10.1097/fjc.0b013e3181e2bfcf
View Full Paper
Ask AI
Bookmark
Share